The pharmacokinetics and relative bioavailability were studied in 18 healthy volunteers. A single oral dose of 150 mg irbesartan capsule (test) or tablet (reference) was given to each volunteer according to a randomized 2-way crossover study. The concentrations in plasma were determined by HPLC-UV method. The main parameters of irbesartan capsules were: Cmax: 1.502 +/- 0.295 micrograms/ml, tmax: 1.44 +/- 0.34 h, t 1/2: 20.21 +/- 14.71 h, AUC0-t: 11.087 +/- 3.443 micrograms/ml-1.h. The relative bioavailability of capsule to tablet was (101.4 +/- 28.9)%. The results of statistical analysis showed that two formulations were bioequivalent.
Biological Availability ; Biphenyl Compounds/blood ; Biphenyl Compounds/*pharmacokinetics ; Capsules ; Cross-Over Studies ; Receptors, Angiotensin/*antagonists & inhibitors ; Tablets ; Tetrazoles/blood ; Tetrazoles/*pharmacokinetics

The pharmacokinetics and relative bioavailability were studied in 18 healthy volunteers. A single oral dose of 150 mg irbesartan capsule (test) or tablet (reference) was given to each volunteer according to a randomized 2-way crossover study. The concentrations in plasma were determined by HPLC-UV method. The main parameters of irbesartan capsules were: Cmax: 1.502 +/- 0.295 micrograms/ml, tmax: 1.44 +/- 0.34 h, t 1/2: 20.21 +/- 14.71 h, AUC0-t: 11.087 +/- 3.443 micrograms/ml-1.h. The relative bioavailability of capsule to tablet was (101.4 +/- 28.9)%. The results of statistical analysis showed that two formulations were bioequivalent.
Adult ; Angiotensin Receptor Antagonists ; Biological Availability ; Biphenyl Compounds ; blood ; pharmacokinetics ; Capsules ; Cross-Over Studies ; Humans ; Male ; Tablets ; Tetrazoles ; blood ; pharmacokinetics

Bicyclol is a new generation of anti-hepatitis drug with China's own intellectual property rights. The chemical structure of bicyclol is new and original. Pharmacological research showed that it has high clinical efficacy in treating chronic hepatitis (HBV) patients and lower side effects. Two metabolites of bicyclol have been isolated: M2 (4-hydroxy-4'-methoxy-5, 6, 5', 6'-bis (methylenedioxy)-2-hydroxylmethyl-2'-methoxycarbonyl biphenyl) and M3 (4'-hydroxy-4-methoxy-5, 6, 5', 6'-bis (methyl enedioxy)-2-hydroxylmethyl-2'-methoxycarbonyl biphenyl). To further study the mechanism, safety, and effectiveness of bicyclol, the M2 and M3 have been total synthesized. The synthesis route is as following: the carboxyl and phenolic hydroxyl group of the aromatic bromide had been separately protected by bromobenzyl, coupling through the intermolecular asymmetric Ullmann reaction and then catalyst hydrogenated, borane reducted, two metabolites of bicyclol M2 and M3 were obtained. The structures were determined by IR, 1H NMR, HRMS. Comparison of hepatoprotective activity of bicyclol and the two metabolites on experimental liver injury, the potency of the metabolites were lower than that of bicyclol.
Alanine Transaminase ; blood ; Animals ; Benzodioxoles ; chemical synthesis ; chemistry ; pharmacology ; Biphenyl Compounds ; metabolism ; Carbon Tetrachloride Poisoning ; Chemical and Drug Induced Liver Injury ; blood ; etiology ; Mice

To investigate the effects of the free radical, 1,1-Diphenyl-2-picylhydrazyl, on cochlear blood flow, 20 guinea pigs were divided into 3 groups at random, 6 for control group, 6 for 1 mmol/L group and 8 for 0.1 mmol/L group. 2 microliters vehicle or drugs were dropped into round window membrane (RWM). Cochlear microcirculation was monitored by laser Doppler flowmeter (LDF), and mean arterial blood flow (MABP), which was transferred by pressure conductor sensor and preamplifier, was simultaneously recorded on the computer. Our results showed that MABP was stable throughout the experiment. Cochlear blood flow (CBF) increased by 10.32% (P < 0.05) in 1 mmol/L group, and decreased by 4.89% in 0.1 mmol/L group (P < 0.05). In control group cochlear microcirculation showed no significant changes. It is concluded that DPPH exerted effects on cochlear microcirculation.
Animals ; Biphenyl Compounds ; Blood Flow Velocity ; Cochlea ; blood supply ; Free Radicals ; pharmacology ; Guinea Pigs ; Laser-Doppler Flowmetry ; Microcirculation ; drug effects ; Picrates ; pharmacology ; Random Allocation

The aim of this study was to investigate the effect of the novel antihepatitis drug bicyclol on the gene expression profiles in concanavalin A (Con A) intoxicated mice by using cDNA microarray analysis. Bicyclol (250 mg x kg(-1)) was given orally to mice three doses before Con A intravenous injection (26.5 mg x kg(-1)). Serum levels of aminotransferases were examined by biochemical methods. Liver mRNA was extracted and reversely transcribed to cDNA with the incorporation of labeled Cy3-dUTP and Cy5-dUTP, separately. The probes were hybridized to the cDNA microarray. The acquired image was scanned and analyzed by Cenepix Pro 3.0 software. Microarray analysis showed that 287 genes exhibited differential expression in bicyclol group, in which 121 genes were up-regulated and 166 genes were down-regulated comparing with that of untreated Con A intoxicated mice. The differential gene expression after bicyclol treatment was involved in the biotransformation, protein synthesis, degradation and circadian rhythm, proliferation and signal transduction. Bicyclol might regulate a series of genes expressions in Con A intoxicated mice.
Alanine Transaminase ; blood ; Animals ; Aspartate Aminotransferases ; blood ; Biphenyl Compounds ; pharmacology ; Chemical and Drug Induced Liver Injury ; blood ; etiology ; genetics ; Concanavalin A ; Gene Expression Profiling ; Male ; Mice ; Mice, Inbred ICR ; Oligonucleotide Array Sequence Analysis ; Random Allocation

AIMTo study the different biological activities of the enantiomers of the anti-hepatitis drug (+/-)-bicyclol, the (+/-)-bicyclol was resolved.

METHODSBy being treated with optically active alkaloid, the two diastereoisomers alkaloid salts of the compound could be obtained, separately. After decomposing and methylating, they were transformed separately into (-)-bicyclol and (+)-bicyclol.

RESULTSThe two enantiomers of bicyclol were determined by melting point, [alpha]D, 1H NMR, MS and chiral column HPLC.

CONCLUSIONComparison of hepatoprotective action of racemic bicyclol and (-)-, (+)-bicyclol on experimental liver injury, the effect of (-)-bicyclol was two times more potent than that of racemic bicyclol and the potency of (+)-bicyclol was much less than that of the racemate.

Alanine Transaminase ; blood ; Animals ; Aspartate Aminotransferases ; blood ; Biphenyl Compounds ; chemical synthesis ; chemistry ; pharmacology ; Carbon Tetrachloride Poisoning ; Chemical and Drug Induced Liver Injury ; blood ; etiology ; Mice ; Molecular Structure ; Optical Rotation ; Stereoisomerism

OBJECTIVETo observe the effect of Tripterygium glycosides (TG) on the expression of hypoxia-inducible factor-1α and endothelin-1 in the kidney of diabetic rats and explore the possible mechanism underlying the protective effect of TG against diabetic nephropathy.

METHODSSixty 8-week-old male SD rats were randomly divided into normal control group (n=10) and streptozotocin-induced diabetes mellitus (DM) model group (n=50). The diabetic model rats were then randomly divided into DM group, low-dose (8 mg/kg) and high-dose (16 mg/kg) TG treatment groups, and Irbesartan (50 mg/kg) treatment group. After 8 weeks, the levels of blood glucose (BG), 24-h urine protein (24 h Upro), serum creatinine (Scr) and blood urea nitrogen (BUN) were measured. The pathological changes in the renal tissues were examined by optical microscopy, and the mean glomerular area (MGA) and mean glomerular volume (MGV) were measured with pathological image analysis. Immunohistochemical and Western blotting were used to detect the expression of HIF-1α and ET-1 protein in the renal tissue, and their mRNA expressions were detected using real-time fluorescence quantitative PCR.

RESULTSHIF-1α and ET-1 expression increased in the kidney of diabetic rats. Compared with the diabetic model rats, the rats receiving TG and Irbesartan treatment showed decreased levels of Scr, BUN, 24h Upro, MGA and MGV, improved renal histopathology, and reduced expression of HIF-1α and ET-1 mRNA and protein in the renal tissue. These changes were more obvious in high-dose TG treatment group. Correlation analysis showed that the expression of HIF-1α was positively correlated with that of ET-1, and they were both positively correlated with kidney weight index (KW/BW), 24 h Upro, MGA, and MGV.

CONCLUSIONHIF-1α and ET-1 are overexpressed in the kidney of diabetic rats. TG can improve kidney damage in diabetic rats and delay the development of diabetic nephropathy by inhibiting the HIF-1α and ET-1 expression.

Animals ; Biphenyl Compounds ; pharmacology ; Blood Glucose ; Blood Urea Nitrogen ; Creatinine ; blood ; Diabetes Mellitus, Experimental ; metabolism ; Endothelin-1 ; metabolism ; Glycosides ; pharmacology ; Hypoxia-Inducible Factor 1, alpha Subunit ; metabolism ; Kidney ; drug effects ; metabolism ; Male ; Rats ; Rats, Sprague-Dawley ; Tetrazoles ; pharmacology ; Tripterygium ; chemistry

OBJECTIVETo investigate the relationship between the genetic polymorphisms of CYP3A5 and the clinical effectiveness of Bicyclol on patients with chronic hepatitis B to make individual medication possible.

METHODS34 cases of chronic hepatitis B were treated by bicyclol tablets for 24 weeks. Liver function indexes (ALT and AST) were determined before and after treatment. Blood CYP3A5 genotyping of each patient was determined by the PCR-RFLP analysis.

RESULTSAll subjects were genotyped for the CYP3A5*3 gene and divided into different group. The groups comprised subjects with CYP3A5*3 carriers (n=18) and CYP3A5*1 carriers (n=16) which include CYP3A5*1/*1 (n=2) and CYP3A5*1/*3 (n=14). Compared with pre-treatment, the serum ALT and AST levels were decreased obviously in all patients. The mean percentage reduction of serum ALT and AST levels were significantly greater in subjects with CYP3A5*3 carriers (79.73% and 74.76%) than in those with CYP3A5*1 carriers (65.90% and 49.63%; P < 0.05) The recovery rates of ALT and AST were significantly highter in CYP3A5*3 carriers than those in CYP3A5*1 carriers (P < 0.05).

CONCLUSIONCYP3A5 genotype has an impact on the therapeutic effects of Bicyclol. The subjects with CYP3A5*3 carriers is more effective than the subjects with CYP3A5*1 carriers. CYP3A5 genotyping may be helpful in predicting therapeutic effects of Bicyclol especially in the terms of decreasing ALT and AST.

Adolescent ; Adult ; Alanine Transaminase ; blood ; Biphenyl Compounds ; pharmacology ; therapeutic use ; Cytochrome P-450 CYP3A ; genetics ; Female ; Genotype ; Hepatitis B, Chronic ; blood ; drug therapy ; genetics ; physiopathology ; Humans ; Liver ; drug effects ; enzymology ; physiopathology ; Male ; Middle Aged ; Polymorphism, Genetic

OBJECTIVETo evaluate the therapeutic effects of bicyclol combined with ganciclocir on infantile cytomegalovirus hepatitis.

METHODSSeventy infants with cytomegalovirus hepatitis were randomized into treatment group (n=35) and control group (n=35) for a 2-week-long treatment with ganciclocir (5 mg/kg) with and without oral bicyclol (3 mg/kg, twice daily), respectively.

RESULTSIn both groups, significant changes occurred in the levels of alanine aminotransferase, alkaline phosphatase, serum total bilirubin, serum total bile acid, and glutamyl transpeptidase after the 2-week treatment (P<0.01); these parameters differed significantly between the two groups after the treatment (P<0.01). Compared with those in the control group, the infants in the treatment group showed significantly better responses to the treatment (P<0.05) with a significantly higher rate of serum anti CMV IgM negativity (P<0.05).

CONCLUSIONSBicyclol combined with ganciclocir can reduce glutamic pyruvic transaminase, alkaline phosphatase and serum total bilirubin, and decrease bile acid levels to lessen liver cell damage and promote the recovery of liver cells.

Alanine Transaminase ; metabolism ; Alkaline Phosphatase ; metabolism ; Antiviral Agents ; therapeutic use ; Bilirubin ; blood ; Biphenyl Compounds ; therapeutic use ; Cytomegalovirus ; Cytomegalovirus Infections ; drug therapy ; Drug Therapy, Combination ; Ganciclovir ; therapeutic use ; Hepatitis ; drug therapy ; virology ; Humans ; Infant ; Liver Function Tests

Adult ; Aged ; Angiotensin II Type 2 Receptor Blockers ; Biphenyl Compounds ; therapeutic use ; Blood Pressure ; drug effects ; Female ; Heart Rate ; drug effects ; Humans ; Male ; Middle Aged ; Syncope, Vasovagal ; drug therapy ; physiopathology ; Tetrazoles ; therapeutic use